A-366833: A novel nicotinonitrile-substituted 3,6-diazabicyclo[3.2.0]-heptane α4β2 nicotinic acetylcholine receptor selective agonist: Synthesis, analgesic efficacy and tolerability profile in animal models

Biochemical Pharmacology

Volumn 74, Issue 8, 2007, Pages 1253-1262

  Ji, Jianguo ^a   Bunnelle, William H ^a   Anderson, David J ^a   Faltynek, Connie ^a   Dyhring, Tino ^b   Ahring, Philip K ^b   Rueter, Lynne E ^a   Curzon, Peter ^a   Buckley, Michael J ^a   Marsh, Kennan C ^a   Kempf Grote, Anita ^a   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

^b NEUROSEARCH A S   (Denmark)

Author keywords

A 366833; Emesis; Epibatidine; nAChR; Nicotine; Pain

Indexed keywords

5 (3,6 DIAZABICYCLO[3.2.0]HEPTAN 3 YL)NICOTINONITRILE; 5 (3,6 DIAZABICYCLO[3.2.0]HEPTAN 6 YL)NICOTINONITRILE; A 365193; A 366833; A 369452; A 424600; FORMALDEHYDE; MECAMYLAMINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EMBRYO; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; VOMITING;

ANALGESICS; ANIMALS; CYSTINE; FERRETS; MALE; MICE; MODELS, ANIMAL; NAUSEA; NICOTINIC AGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NICOTINIC;

EID: 34548674477     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.010     Document Type: Article

References (48)

1. Kennedy J.D. Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem 50 (2007) 2547-2556
2. Jensen A.A., Frolund B., Liljefors T., and Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structure revelations, targets identifications, and therapeutic inspirations. J Med Chem 48 (2005) 4705-4745
3. Bunnelle W.H., Dart M.J., and Schrimpf M.R. Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity. Curr Med Chem 4 (2004) 299-334
4. Decker M.W., Rueter L.R., and Bitner R.C. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr Top Med Chem 4 (2004) 369-384
5. Decker M. Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain. Drug Dev Res 67 (2006) 355-359
6. Rueter L.E., Donnelly-Roberts D.L., Curzon P., Briggs C.A., Anderson D.J., and Bitner R.S. A-85380: a pharmacological probe for the preclinical and clinical investigation of the α4β2 neuronal nicotinic acetylcholine receptor. CNS Drug Rev 12 (2006) 100-112
7. Damaj M.I., Wiley J.L., Martin B.R., and Papke R.L. In vivo characterization of a novel inhibitor of CNS nicotinic receptors. Eur J Pharmol 521 (2005) 43-48
8. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., et al. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 279 (1998) 77-81
9. Andrews P.L.R., Friedman A.I., Liu Y., Smith J.E., and Sims D.W. Potential energetic implications of emesis in the house musk shrew (Suncus murinus). Physiol Behav 84 (2005) 519-524
10. Rudd J.A., and Wai M.K. Genital grooming and emesis induced by vanilloids in Suncus murinus, the house musk shrew. Eur J Pharmcol 422 (2001) 185-195
11. Boyce S., Webb J.K., Shepheard S.L., Russell M.G.N., and Rupniak N.M.J. Anagesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain 85 (2000) 443-450
12. Beleslin D.B., and Krstic S.K. Further studies on nicotine-induced emesis: nicotinic mediation in area postrema. Physiol Behav 39 (1987) 681-686
13. Spealman R.D. Maintenance of behavior by postponement of scheduled injections of nicotine in squirrel monkeys. J Pharmcol Exp Ther 227 (1983) 154-159
14. Sullivan J.P., and Bannon A.W. Epibatidine: pharmacological properties of a novel nicotinic acetylchloine receptor agonist and analgesic agent. CNS Drug Rev 2 (1996) 21-39
15. Millar N.S. Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem Soc Trans 31 (2003) 869-874
16. Khan I.M., Stanislaus S., Zhang L., Taylor P., and Yaksh T.L. A-85380 and epibatidine each interact with disparate spinal nicotinic receptor subtypes to achieve analgesia and nociception. J Pharmacol Exp Ther 297 (2001) 230-239
17. Cucchiaro G., Chaijale N., and Commons K.G. The dorsal raphe nucleus as a site of action of the antinociceptive and behaviral effects of the α4 nicotinic receptor agonist epibatidine. J Pharmacol Exp Ther 313 (2005) 389-394
18. Rueter L.E., Kohlhaas K.L., Curzon P., Surowy C.S., and Meyer M.D. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 103 (2003) 269-276
19. Bitner R.S., Nikkel A.L., Curzon P., Donnelly-Roberts D.L., Puttfarcken P.S., Namovic M., et al. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res 871 (2000) 66-74
20. Marubio L.M., del Mar Arroyo-Jimenez M., Cordero-Erausquin M., Lena C., Le Novere N., de Kerchove d'Exaerde A., et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 398 (1999) 805-810
21. Picciotto M.R., Zoli M., Rimondini R., Lena C., Marubio L.M., Pich E.M., et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
22. Vincler M., and McIntosh J.M. Targeting the α9α10 nicotinic acetylcholine receptor to treat severe pain. Expert Opin Ther Targets 11 (2007) 891-897
23. Vincler M., Wittenauer S., Parker R., Ellison M., Olivera B.M., and McIntosh J.M. Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors. Proc Natl Acad Sci USA 103 (2006) 17880-17884
24. Gomez-Casati M.E., Fuchs P.A., Elgoyhen A.B., and Katz E. Biophysical and pharmacological characterization of nicotinic cholinergic receptors in rat cochlear inner hair cells. J Physiol 566 (2005) 103-118
25. Ji J, Schrimpf MR, Sippy KB, Bunnelle WH, Li T, Anderson DJ, et al. Synthesis and structure-activity relationship (SAR) studies of 3,6-diazabicyclo[3.2.0]-heptanes as novel α4β2 nicotinic acetylcholine receptor (nAChR) selective agonists. J Med Chem 2007;50:in press.
26. 3H]-Cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 39 (1991) 9-12
27. 3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 96 (2002) 99-105
28. Bannon A.W., Decker M.W., Curzon P., Buckley M.J., Kim D.J., Radek R.J., et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. In vivo characterization. J Pharmacol Exp Ther 285 (1998) 787-794
29. Damaj M.I., Glassco W., Aceto M.D., and Martin B.R. Antinocieptive responses of metanicotine, a selective nicotinic agonist. J Pharmacol Exp Ther 291 (1999) 390-398
30. Kim S.H., and Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50 (1992) 355-363
31. Osinski M.A., Uchic M.E., Seifert T., Shaughnessy T.K., Miller L.N., Nakane M., et al. Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behavior 81 (2005) 211-219
32. Osinski M.A., Seifert T.R., Shaughnessy T.K., Gintant G.A., and Cox B.F. Emetic libility testing in ferrets. In: Enna S.J., William M., Ferkany J.W., Kenakin T., Porsolt R.D., and Sullivan J.P. (Eds). Current protocols in pharmacology (2003), John Wiley Sons, New York 5.31.1-5.31.8
33. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol Pharmacol 48 (1995) 280-287
34. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., and Kellar K.J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41 (1992) 31-37
35. Anderson D.J., Williams M., Arneric S.P., Pauly J.R., Rotert G.A., Raszkiewicz J.L., et al. Characterization of [3H]-ABT-418: a novel cholinergic channel ligand. J Pharmacol Exp Ther 273 (1995) 1434-1441
36. Fitch R.W., Xiao Y., Kellar K.J., and Daly J.W. Membrane potential fluorescence: a rapid and highly sensitive assay for nicotinic receptor channel function. Proc Natl Acad Sci USA 100 (2003) 4909-4914
37. Kuntzweiler T.A., Arneric S.P., and Donnelly-Roberts D.L. Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR. Drug Dev Res 44 (1998) 14-20
38. Curzon P., Nikkel A.L., Bannon A.W., Arneric S.P., and Decker M.W. Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (±)-epibatidine in rats. J Pharmacol Exp Ther 287 (1998) 847-853
39. Sullivan JP. Neuroscience and pain. http://media.corporateir.net/media_files/nys/abt/rdday/NeuroPain.pdf.
40. Davis L., Pollock L.J., and Stone T.T. Visceral pain. Surg Gynecol Obstet 55 (1932) 418-426
41. Campbell V.C., Taylor R.E., and Tizabi Y. Antinociceptive effects of alcohol and nicotine: involvement of the opioid system. Brain Res 1097 (2006) 71-77
42. Cepeda-Benito A., Reynoso J.T., Davis K.W., Susabda A., Mendez I.A., and Harraid J.H. Interdose interval effects on the development of contextual tolerance to nicotine's analgesic effects in rats (Rattus norvegicus). Exp Clin Psychopharm 14 (2006) 180-189
43. Cepeda-Benito A., Davis K.W., Reynoso J.T., and Harraid J.H. Associative and behavioral tolerance to the analgesic effects of nicotine in rats: tail-flick and paw-lick assays. Psychopharmacology 180 (2005) 224-233
44. Glennon R.A. Nicotine and pain. Med Chem Res 13 (2004) 74-77
45. Tripathi H.L., Martin B.R., and Aceto M.D. Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther 221 (1982) 91-96
46. Daly J.W., Garraffo H.M., Spande T.F., Decker M.W., Sullivan J.P., and Williams M. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opoid analgesics. Nat Prod Rep 17 (2000) 131-135
47. Badio B., Garraffo H.M., Spande T.F., and Daly J.W. Epibatidine: discovery and definition as a potent analgesic and nicotinic agonist. Med Chem Res 4 (1994) 440-448
48. Badio B., and Daly J.W. Epibatidines: a potent analgesic and nicotinic agonist. Mol Pharmacol 45 (1994) 563-569